Two new drugs join forces with chemo to tackle tough lymphoma
NCT ID NCT06977711
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests whether adding two drugs—loncastuximab and roflumilast—to the standard R-CHOP chemotherapy regimen can safely treat people with untreated, high-risk diffuse large B-cell lymphoma (DLBCL). The study enrolls about 10 adults with this aggressive lymphoma who have not received prior therapy. Researchers will monitor side effects and measure how well the tumors respond to treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
loncastuximab, roflumilast, rituximab, cyclophosphamide, vincristine, doxorubicin, prednisone
What this could lead to
If successful, this combination could improve outcomes for people with high-risk DLBCL, potentially leading to a more effective first-line treatment.
What could go wrong
This is a very early phase 1 trial with only 10 participants, so safety and effectiveness are not yet established. Adding more drugs may increase side effects without improving results.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Hospital System
RECRUITINGSan Antonio, Texas, 78228, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Texas Health Science Center San Antonio at the Cancer Therapy and Research Center
RECRUITINGSan Antonio, Texas, 78229, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••